Ackloo S., Antolin AA., Bartolome JM., Beck H., Bullock A., Betz UAK., Böttcher J., Brown PJ., Chaturvedi M., Crisp A., Daniels D., Dreher J., Edfeldt K., Edwards AM., Egner U., Elkins J., Fischer C., Glendorf T., Goldberg S., Hartung IV., Hillisch A., Homan E., Knapp S., Köster M., Krämer O., Llaveria J., Lessel U., Lindemann S., Linderoth L., Matsui H., Michel M., Montel F., Mueller-Fahrnow A., Müller S., Owen DR., Saikatendu KS., Santhakumar V., Sanderson W., Scholten C., Schapira M., Sharma S., Shireman B., Sundström M., Todd MH., Tredup C., Venable J., Willson TM., Arrowsmith CH.

Target 2035, an international federation of biomedical scientists from the public and private sectors, is leveraging 'open' principles to develop a pharmacological tool for every human protein. These tools are important reagents for scientists studying human health and disease and will facilitate the development of new medicines. It is therefore not surprising that pharmaceutical companies are joining Target 2035, contributing both knowledge and reagents to study novel proteins. Here, we present a brief progress update on Target 2035 and highlight some of industry's contributions.

Target 2035 - an update on private sector contributions.

DOI

Type

Journal

Publication Date

Volume

Pages